Trials / Completed
CompletedNCT03108664
HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)
HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 330 (actual)
- Sponsor
- Sylentis, S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether SYL1001 ophthalmic solution is safe and effective in the treatment of signs and symptoms of Dry Eye Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SYL1001 ophthalmic solution | 1 drop in the affected eye |
| DRUG | Vehicle opthalmic solution | 1 drop in the affected eye |
Timeline
- Start date
- 2017-05-18
- Primary completion
- 2018-10-16
- Completion
- 2018-11-16
- First posted
- 2017-04-11
- Last updated
- 2019-02-15
Locations
40 sites across 6 countries: Estonia, Germany, Italy, Portugal, Slovakia, Spain
Source: ClinicalTrials.gov record NCT03108664. Inclusion in this directory is not an endorsement.